Protara Therapeutics, Inc.
NASDAQ:TARA
3.24 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.948 | 0 | 0 |
| Cost of Revenue
| 0 | 0.341 | 0.247 | 1.167 | 0.196 | 0.016 | 0.115 | 0.148 | 0.123 | 0.057 | 0 | 0.027 | 0.057 |
| Gross Profit
| 0 | -0.341 | -0.247 | -1.167 | -0.196 | -0.016 | -0.115 | -0.148 | -0.123 | -0.057 | 2.948 | -0.027 | -0.057 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 31.704 | 24.785 | 16.808 | 21.088 | 11.982 | 6.438 | 15.506 | 21.686 | 18.869 | 12.381 | 6.432 | 3.994 | 5.907 |
| General & Administrative Expenses
| 17.45 | 18.624 | 20.737 | 26.401 | 22.462 | 8.816 | 10.574 | 0.106 | 9.836 | 8.489 | 4.096 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.422 | -0.123 | -0.057 | 0 | 0 | 0 |
| SG&A
| 17.45 | 18.624 | 20.737 | 26.401 | 22.462 | 8.816 | 10.574 | 8.528 | 9.713 | 8.432 | 4.096 | 3.101 | 2.032 |
| Other Expenses
| 0 | 0 | 29.517 | 0 | 0 | 0 | 0.207 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 49.154 | 43.613 | 37.545 | 47.489 | 34.444 | 15.254 | 26.08 | 30.214 | 28.582 | 20.813 | 10.528 | 7.095 | 7.939 |
| Operating Income
| -49.154 | -43.613 | -67.062 | -47.489 | -34.444 | -15.254 | -26.08 | -30.362 | -28.705 | -20.87 | -7.58 | -7.122 | -7.996 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.571 | 0 | 0 |
| Total Other Income Expenses Net
| 4.558 | 3.193 | 1.11 | 0.237 | 0.466 | 0 | 0.643 | 0.398 | 0.179 | -0.507 | 4.238 | -0.79 | 0.026 |
| Income Before Tax
| -44.596 | -40.42 | -65.952 | -47.252 | -33.978 | -14.992 | -25.437 | -29.964 | -28.526 | -21.377 | -3.342 | -7.912 | -7.97 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.134 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -1.137 | -0.117 | -0.466 | -0.262 | 5.351 | 0.657 | 0.372 | -0.363 | 5.095 | 0 | 0 |
| Net Income
| -44.596 | -40.42 | -64.815 | -47.135 | -33.512 | -14.73 | -25.437 | -29.964 | -28.526 | -21.377 | -3.342 | -7.912 | -7.97 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.134 | 0 | 0 |
| EPS
| -2.17 | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS Diluted
| -2.17 | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
| EBITDA
| -49.154 | -43.272 | -64.568 | -46.085 | -33.782 | -7.814 | -20.614 | -29.816 | -28.403 | -21.32 | -2.455 | -7.024 | -7.913 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.833 | 0 | 0 |